CN105125799A - Medicine composition for treating bone fractures and preparing method of medicine composition - Google Patents
Medicine composition for treating bone fractures and preparing method of medicine composition Download PDFInfo
- Publication number
- CN105125799A CN105125799A CN201510651443.1A CN201510651443A CN105125799A CN 105125799 A CN105125799 A CN 105125799A CN 201510651443 A CN201510651443 A CN 201510651443A CN 105125799 A CN105125799 A CN 105125799A
- Authority
- CN
- China
- Prior art keywords
- parts
- radix
- pharmaceutical composition
- fracture
- medicine composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 208000010392 Bone Fractures Diseases 0.000 title claims abstract description 37
- 239000003814 drug Substances 0.000 title claims abstract description 31
- 239000000203 mixture Substances 0.000 title claims abstract description 25
- 238000000034 method Methods 0.000 title abstract description 3
- 229940079593 drug Drugs 0.000 title description 7
- 239000002994 raw material Substances 0.000 claims abstract description 13
- 238000002360 preparation method Methods 0.000 claims abstract description 11
- 239000008194 pharmaceutical composition Substances 0.000 claims description 45
- 206010017076 Fracture Diseases 0.000 claims description 35
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 31
- 239000000843 powder Substances 0.000 claims description 27
- 239000000706 filtrate Substances 0.000 claims description 20
- 238000001914 filtration Methods 0.000 claims description 20
- 241000756943 Codonopsis Species 0.000 claims description 19
- 239000009286 sanguis draxonis Substances 0.000 claims description 19
- 238000001035 drying Methods 0.000 claims description 12
- 240000000249 Morus alba Species 0.000 claims description 11
- 235000008708 Morus alba Nutrition 0.000 claims description 11
- 238000004140 cleaning Methods 0.000 claims description 11
- 238000003756 stirring Methods 0.000 claims description 10
- 238000001816 cooling Methods 0.000 claims description 6
- 238000002156 mixing Methods 0.000 claims description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 6
- 239000012467 final product Substances 0.000 claims description 5
- 238000007602 hot air drying Methods 0.000 claims description 5
- 239000012535 impurity Substances 0.000 claims description 5
- 238000002791 soaking Methods 0.000 claims description 5
- 238000005406 washing Methods 0.000 claims description 5
- 210000000582 semen Anatomy 0.000 claims description 4
- 239000002775 capsule Substances 0.000 claims description 3
- 239000008187 granular material Substances 0.000 claims description 2
- 239000006187 pill Substances 0.000 claims description 2
- 239000008280 blood Substances 0.000 abstract description 22
- 210000004369 blood Anatomy 0.000 abstract description 22
- 210000000988 bone and bone Anatomy 0.000 abstract description 15
- 230000000694 effects Effects 0.000 abstract description 15
- 230000001737 promoting effect Effects 0.000 abstract description 13
- 238000005728 strengthening Methods 0.000 abstract description 8
- 244000303040 Glycyrrhiza glabra Species 0.000 abstract description 2
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 abstract description 2
- 210000002435 tendon Anatomy 0.000 abstract description 2
- 241000007126 Codonopsis pilosula Species 0.000 abstract 1
- 240000008067 Cucumis sativus Species 0.000 abstract 1
- 235000010799 Cucumis sativus var sativus Nutrition 0.000 abstract 1
- 241000112528 Ligusticum striatum Species 0.000 abstract 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 abstract 1
- 235000011477 liquorice Nutrition 0.000 abstract 1
- 208000002193 Pain Diseases 0.000 description 20
- 230000036407 pain Effects 0.000 description 18
- 230000017531 blood circulation Effects 0.000 description 11
- 230000006378 damage Effects 0.000 description 8
- 208000014674 injury Diseases 0.000 description 8
- 239000000047 product Substances 0.000 description 8
- 230000008961 swelling Effects 0.000 description 8
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 7
- 230000037182 bone density Effects 0.000 description 7
- 239000011575 calcium Substances 0.000 description 7
- 229910052791 calcium Inorganic materials 0.000 description 7
- 210000004185 liver Anatomy 0.000 description 7
- 241000283973 Oryctolagus cuniculus Species 0.000 description 6
- 208000024891 symptom Diseases 0.000 description 6
- 208000027418 Wounds and injury Diseases 0.000 description 5
- 235000009508 confectionery Nutrition 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 238000005516 engineering process Methods 0.000 description 5
- 235000021251 pulses Nutrition 0.000 description 5
- 210000000952 spleen Anatomy 0.000 description 5
- 210000003734 kidney Anatomy 0.000 description 4
- 210000004072 lung Anatomy 0.000 description 4
- 230000002175 menstrual effect Effects 0.000 description 4
- 210000003205 muscle Anatomy 0.000 description 4
- 208000037921 secondary disease Diseases 0.000 description 4
- 239000003440 toxic substance Substances 0.000 description 4
- 208000006820 Arthralgia Diseases 0.000 description 3
- 206010014080 Ecchymosis Diseases 0.000 description 3
- 206010060891 General symptom Diseases 0.000 description 3
- 239000002671 adjuvant Substances 0.000 description 3
- 230000007812 deficiency Effects 0.000 description 3
- 238000005469 granulation Methods 0.000 description 3
- 230000003179 granulation Effects 0.000 description 3
- 238000011835 investigation Methods 0.000 description 3
- 231100000614 poison Toxicity 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 206010011224 Cough Diseases 0.000 description 2
- 241000125183 Crithmum maritimum Species 0.000 description 2
- 208000012661 Dyskinesia Diseases 0.000 description 2
- 206010019233 Headaches Diseases 0.000 description 2
- 208000002565 Open Fractures Diseases 0.000 description 2
- 206010061363 Skeletal injury Diseases 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 206010049514 Traumatic fracture Diseases 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 230000004064 dysfunction Effects 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 210000003414 extremity Anatomy 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 231100000869 headache Toxicity 0.000 description 2
- 230000035876 healing Effects 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 230000035935 pregnancy Effects 0.000 description 2
- 108010048734 sclerotin Proteins 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 238000010998 test method Methods 0.000 description 2
- 230000008733 trauma Effects 0.000 description 2
- 230000008736 traumatic injury Effects 0.000 description 2
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 241001254604 Angelica pubescens Species 0.000 description 1
- 241000717739 Boswellia sacra Species 0.000 description 1
- 241000208671 Campanulaceae Species 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- 241000721047 Danaus plexippus Species 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 241001489978 Eupolyphaga Species 0.000 description 1
- 239000004863 Frankincense Substances 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 241001278898 Glycyrrhiza inflata Species 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 239000009636 Huang Qi Substances 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010062717 Increased upper airway secretion Diseases 0.000 description 1
- 208000015817 Infant Nutrition disease Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 206010024453 Ligament sprain Diseases 0.000 description 1
- 208000032912 Local swelling Diseases 0.000 description 1
- 208000019255 Menstrual disease Diseases 0.000 description 1
- 241000218231 Moraceae Species 0.000 description 1
- 241001057584 Myrrha Species 0.000 description 1
- 244000021150 Orbignya martiana Species 0.000 description 1
- 235000014643 Orbignya martiana Nutrition 0.000 description 1
- 235000003143 Panax notoginseng Nutrition 0.000 description 1
- 241000180649 Panax notoginseng Species 0.000 description 1
- 208000028017 Psychotic disease Diseases 0.000 description 1
- 208000025747 Rheumatic disease Diseases 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 206010042674 Swelling Diseases 0.000 description 1
- 206010053476 Traumatic haemorrhage Diseases 0.000 description 1
- 206010047513 Vision blurred Diseases 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 1
- 229940126678 chinese medicines Drugs 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000000249 desinfective effect Effects 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 208000001848 dysentery Diseases 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 230000004438 eyesight Effects 0.000 description 1
- 210000003194 forelimb Anatomy 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 230000002607 hemopoietic effect Effects 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 210000001624 hip Anatomy 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 210000000629 knee joint Anatomy 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 235000021374 legumes Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000012567 medical material Substances 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 230000003119 painkilling effect Effects 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 210000003516 pericardium Anatomy 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 208000026435 phlegm Diseases 0.000 description 1
- 208000037920 primary disease Diseases 0.000 description 1
- 230000002040 relaxant effect Effects 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 230000000552 rheumatic effect Effects 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 206010040872 skin infection Diseases 0.000 description 1
- QGMRQYFBGABWDR-UHFFFAOYSA-N sodium;5-ethyl-5-pentan-2-yl-1,3-diazinane-2,4,6-trione Chemical compound [Na+].CCCC(C)C1(CC)C(=O)NC(=O)NC1=O QGMRQYFBGABWDR-UHFFFAOYSA-N 0.000 description 1
- 210000004872 soft tissue Anatomy 0.000 description 1
- 238000012109 statistical procedure Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- -1 tabletting Substances 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 231100000167 toxic agent Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 229940126680 traditional chinese medicines Drugs 0.000 description 1
- 210000003932 urinary bladder Anatomy 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/232—Angelica
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/236—Ligusticum (licorice-root)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/34—Campanulaceae (Bellflower family)
- A61K36/344—Codonopsis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/42—Cucurbitaceae (Cucumber family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/484—Glycyrrhiza (licorice)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/60—Moraceae (Mulberry family), e.g. breadfruit or fig
- A61K36/605—Morus (mulberry)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/889—Arecaceae, Palmae or Palmaceae (Palm family), e.g. date or coconut palm or palmetto
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/10—Preparation or pretreatment of starting material
- A61K2236/15—Preparation or pretreatment of starting material involving mechanical treatment, e.g. chopping up, cutting or grinding
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/53—Liquid-solid separation, e.g. centrifugation, sedimentation or crystallization
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses a medicine composition for treating bone fractures and a preparing method of the medicine composition and belongs to the technical field of traditional Chinese medicine. The medicine composition is prepared from circium japonicum, sangusis draconis, codonopsis pilosula, radix angelicae pubescentis, ligusticum wallichii, folium mori, cucumber seeds, sargentg loryvine stems, liquorice and other raw materials. The medicine composition has the obvious treating advantages of invigorating qi to nourish the blood, enriching the blood and qi, promoting the blood to remove stasis, supporting body resistance, strengthening tendons and bones and the like on the aspect of treating the bone fractures. In addition, the medicine composition has the advantages of being stable in preparation medicine effect, wide in application range, easy to apply and popularize and the like.
Description
Technical field
The invention belongs to technical field of Chinese medicines, particularly relate to a kind of pharmaceutical composition for the treatment of fracture and preparation method thereof.
Background technology
Fracture is that the integrity of phalanges or seriality are damaged caused, the disease being main manifestations with pain, swelling, livid purple, dysfunction, deformity and bony crepitus etc.Its clinical main manifestations is: fractures has localized pain and tenderness, local swelling and occur ecchymosis, limb function position or completely lose, and completeness sclerotin still can occur cacomelia and abnormal movement.Fracture is a kind of commonly encountered diseases, is the clinical frequently-occurring disease of orthopaedic trauma, can damages social labor power, the health of the serious harm mankind.According to investigations, the prevalence of China's fracture is about 1.4%, and because China's population base is comparatively large, the fracture patient of existence is also more.Although the Chinese medicine of current treatment this respect disease is a lot, but majority also exists, and reducing swelling and alleviating pain is slow, the course for the treatment of is long, the dissatisfactory shortcoming of effect, doctor trained in Western medicine is when treating the comparatively serious bone injury of this respect and being sick, normally by the position of bone righting of patient part, then medical apparatus and instruments is used to be carried out internal fixtion, or carry out extenal fixation, resting slowly with Gypsum Fibrosum, binder, clamping plate etc.This western medicine therapy utilizing operation and medicine, weak point is that sufferer healing recovers comparatively slow, and treatment cycle is longer, and medical expense is high, and in process, patient is more painful.If meet the patient of unsuitable operative treatment, this Therapeutic Method just has certain limitation.
Chinese invention patent 201310238201.0 discloses a kind of Chinese medicine composition for the treatment of fracture, and the raw materials of this Chinese medicine composition comprises: Semen Strychni 10-30 part, Herba Artemisiae Anomalae 10-40 part, Radix Astragali 10-50 part, Cortex Eucommiae 10-20 part, Radix Lamiophlomidis Rotatae 5-10 part, Rhizoma Chuanxiong 5-15 part, Radix Rehmanniae Preparata 5-15 part, Radix Notoginseng 5-15 part, Eupolyphaga Seu Steleophaga 5-15 part, Olibanum 9-15 part, Myrrha 9-15 part, Rhizoma Drynariae 5-15 part, Fructus Chaenomelis 3-8 part and Radix Glycyrrhizae 1.5-9 part.This Chinese medicine composition has effect of kidney tonifying synthetism, expelling pus and promoting granulation, reducing swelling and alleviating pain and heat-clearing and toxic substances removing, but at benefiting QI for activating blood circulation, blood nourishing and calcium replenishing aspect effect is not very remarkable.
Summary of the invention
The technical problem to be solved in the present invention is to provide a kind of pharmaceutical composition for the treatment of fracture, and this pharmaceutical composition can effective blood nourishing and calcium replenishing, QI invigorating QI invigorating, promoting blood circulation to restore menstrual flow, promoting blood circulation to remove blood stasis, the body resistance strengthening and constitution consolidating and bone and muscle strengthening.In addition, the present invention also provides corresponding manufacturing process to be made and facilitate easy-to-use finished product preparation under the prerequisite ensureing curative effect by this Chinese medicine.
In order to solve the problems of the technologies described above, inventor is by the checking repeatedly of clinical practice, and the amount of adjustment medical material and kind, finally invented a kind of brand-new pharmaceutical composition.This pharmaceutical composition is prepared from by the raw material of following parts by weight: Radix Cirsii Japonici 15-30 part, Sanguis Draxonis 15-30 part, Radix Codonopsis 14-28 part, Radix Angelicae Pubescentis 10-20 part, Rhizoma Chuanxiong 12-28 part, Folium Mori 15-20 part, Semen Cucumidis sativi 10-18 part, Caulis Sargentodoxae 10-20 part and Radix Glycyrrhizae 10-20 part.
Preferably, this pharmaceutical composition is prepared from by the raw material of following parts by weight: Radix Cirsii Japonici 15 parts, Sanguis Draxonis 15 parts, Radix Codonopsis 14 parts, Radix Angelicae Pubescentis 10 parts, Rhizoma Chuanxiong 12 parts, 15 parts, Folium Mori, Semen Cucumidis sativi 10 parts, Caulis Sargentodoxae 10 parts and 10 parts, Radix Glycyrrhizae.
Preferably, this pharmaceutical composition is prepared from by the raw material of following parts by weight: Radix Cirsii Japonici 30 parts, Sanguis Draxonis 30 parts, Radix Codonopsis 28 parts, Radix Angelicae Pubescentis 20 parts, Rhizoma Chuanxiong 28 parts, 20 parts, Folium Mori, Semen Cucumidis sativi 18 parts, Caulis Sargentodoxae 20 parts and 20 parts, Radix Glycyrrhizae.
Preferably, this pharmaceutical composition is prepared from by the raw material of following parts by weight: Radix Cirsii Japonici 28 parts, Sanguis Draxonis 28 parts, Radix Codonopsis 20 parts, Radix Angelicae Pubescentis 15 parts, Rhizoma Chuanxiong 16 parts, 18 parts, Folium Mori, Semen Cucumidis sativi 14 parts, Caulis Sargentodoxae 15 parts and 15 parts, Radix Glycyrrhizae.
Preferably, this pharmaceutical composition is made into Chinese medicine decoction, granule, powder, capsule, watered pill or tablet.
Accordingly, the preparation method of pharmaceutical composition of the present invention comprises following step:
(1): get Radix Cirsii Japonici, wash away impurity, 50 DEG C of hot air dryings 5 hours, control moisture is 3%-8%, pulverizes, and crosses 40-60 mesh sieve, obtains coarse powder; Coarse powder is sucked air-stream type ultrafine pulverizer and carry out micronizing, pulverize pressure 0.5MPa, charging rate is 30mg/s, carries out micronizing respectively after drying, crosses 800 mesh sieves, obtains Ultra-fine Powder of Mulberry Leaves, for subsequent use;
(2): get Sanguis Draxonis, Radix Codonopsis, Radix Angelicae Pubescentis, Rhizoma Chuanxiong, Folium Mori, Semen Cucumidis sativi, Caulis Sargentodoxae and Radix Glycyrrhizae, clean, crushed after being dried, add the water soaking 0.5-1 hour of coarse powder total amount 8-13 times amount, then decoct 2-3 time, each 1-2 hour, filter, merging filtrate, filtrate is at 50-65 DEG C, vacuum is survey the clear paste that relative density is 1.10-1.20 under vacuum-concentrcted to 60 DEG C condition under the condition of 0.05-0.08MPa, cooling, slowly adds ethanol while stirring to alcohol content for reaching 40-60%, 4 DEG C of standing 12-24 hour, filter, obtain filtrate A and filtering residue;
(3): the filtering residue obtained in step (2) slowly being added while stirring its weight 4-6 times amount volume fraction is the ethanol of 40-60%, 4 DEG C of standing 3-5 hour, filter, obtain liquor B and filtering residue; Filtering residue uses the washing with alcohol 2-3 time of 40-60% again, collects and merges cleaning mixture;
(4): merge described filtrate A, liquor B and cleaning mixture, survey the thick paste that relative density is 1.10-1.20, drying under reduced pressure under mixing final vacuum is evaporated to 60 DEG C of conditions, pulverize, cross 100-200 mesh sieve, mix with described Ultra-fine Powder of Mulberry Leaves, to obtain final product.
Source, the nature and flavor of the present invention's component used, return through and effect:
Sanguis Draxonis: the resin oozed out for babassu Sanguis Draxonis fruit is through being processed into, sweet, salty is flat; GUIXIN, Liver Channel; To invigorate blood circulation analgesic therapy, removing stasis to stop bleeding, expelling pus and promoting granulation; For traumatic injury, trusted subordinate's stasis of blood pain, traumatic hemorrhage, skin infection is not held back.
Radix Angelicae Pubescentis
:this product is the dry root of samphire Angelica pubescens, acrid in the mouth, hardship, slightly warm in nature; Return kidney, urinary bladder channel; Expelling wind and removing dampness, arthralgia aggravated by cold pain relieving; For anemofrigid-damp arthralgia, wash pain, few cloudy volt wind headache, wind and cold holds wet headache under the arm.
Rhizoma Chuanxiong: this product is the dry rhizome of samphire Rhizoma Chuanxiong; Acrid in the mouth, warm in nature; Return liver, gallbladder, pericardium channel; Blood-activating and qi-promoting, wind-expelling pain-stopping.
Folium Mori: this product is be the dried leaves of moraceae plants Mulberry; Bitter in the mouth, sweet, cold nature; Return lung, Liver Channel; Wind and heat dispersing, clearing away lung-heat to relieve cough, liver heat removing and eyesight improving.
Caulis Sargentodoxae: this product is the dry stem of fallen leaves, bejuco; Nature and flavor are bitter, flat; There is heat-clearing and toxic substances removing, promoting blood circulation to remove obstruction in the collateral, the effect of expellingging wind and relieving convulsion; Rheumatic arthralgia, bloody dysentery, stranguria with blood, menoxenia, infantile malnutrition, worm pain, injury from falling down.
Radix Cirsii Japonici: this product is dry aerial parts or the root of Radix Cirsii Japonici plant; Sweet, bitter, cool; GUIXIN, Liver Channel; Cooling blood for hemostasis, removing blood stasis to reduce swelling.
Radix Codonopsis: this product is the dry root of Campanulaceae Radix Codonopsis; Sweet in the mouth, property is put down; Return spleen, lung meridian; Invigorating the spleen and replenishing QI, spleen invigorating lung benefiting.
Radix Glycyrrhizae: this product is the dry root of glycyrrhizic legume, Glycyrrhiza inflata Bat. or Glycyrrhiza glabra L..Sweet in the mouth, property is put down; GUIXIN, lung, spleen, stomach warp; Invigorating the spleen and replenishing QI, heat-clearing and toxic substances removing, expelling phlegm for arresting cough, relieving spasm to stop pain, coordinating the actions of various ingredients in a prescription.
The prescription analysis of Chinese prescription of the present invention:
Chinese prescription of the present invention is with Sanguis Draxonis, Radix Codonopsis for monarch drug, spirit keeping and blood activating, blood nourishing and calcium replenishing; With Radix Cirsii Japonici, Folium Mori, Rhizoma Chuanxiong for ministerial drug, invigorating QI to consolidate the body surface resistance, promoting blood circulation to restore menstrual flow, stasis-dispelling and pain-killing, with Caulis Sargentodoxae, Semen Cucumidis sativi, Radix Angelicae Pubescentis for adjuvant drug, removing pathogenic heat from blood and toxic substance from the body, replenishes the calcium and keeps fit, wind-expelling pain-stopping, detumescence and promoting granulation; With Radix Glycyrrhizae for making medicine, coordinating the actions of various ingredients in a prescription, makes all medicines arrange in pairs or groups, synergism, jointly reaches the effects such as blood nourishing and calcium replenishing, QI invigorating QI invigorating, promoting blood circulation to restore menstrual flow, promoting blood circulation to remove blood stasis, the body resistance strengthening and constitution consolidating and bone and muscle strengthening, has very significant effect to treatment fracture.
Compared with prior art, the present invention has following technical advantage:
1, each Chinese medicinal components of pharmaceutical composition of the present invention is worked in coordination with, better in the effect in strong bone of fostering the spirit of nobility and replenish the calcium of enriching blood;
2, pharmaceutical composition of the present invention is natural pure Chinese medicinal preparation, and toxic and side effects is little;
3, pharmaceutical composition of the present invention is in treatment fracture, there is the remarkable result of blood nourishing and calcium replenishing, QI invigorating QI invigorating, promoting blood circulation to restore menstrual flow, promoting blood circulation to remove blood stasis, the body resistance strengthening and constitution consolidating and bone and muscle strengthening, in addition, also have preparation efficacy stability, applied widely, be easy to advantages such as applying.
Detailed description of the invention
It will be understood by those skilled in the art that technology disclosed in following examples represents the technology playing good action in the practice of the invention of the present inventor's discovery.But, many changes can be made in disclosed specific embodiments, and still obtain same or analogous result, and not depart from the spirit and scope of the present invention.
embodiment 1:
Raw material is taken: Radix Cirsii Japonici 15 parts, Sanguis Draxonis 15 parts, Radix Codonopsis 14 parts, Radix Angelicae Pubescentis 10 parts, Rhizoma Chuanxiong 12 parts, 15 parts, Folium Mori, Semen Cucumidis sativi 10 parts, Caulis Sargentodoxae 10 parts and 10 parts, Radix Glycyrrhizae by following parts by weight.
Preparation method:
(1): get Radix Cirsii Japonici, wash away impurity, 50 DEG C of hot air dryings 5 hours, controlling moisture is 5%, pulverizes, and crosses 40 mesh sieves, obtains coarse powder; Coarse powder is sucked air-stream type ultrafine pulverizer and carry out micronizing, pulverize pressure 0.5MPa, charging rate is 30mg/s, carries out micronizing respectively after drying, crosses 800 mesh sieves, obtains Ultra-fine Powder of Mulberry Leaves, for subsequent use;
(2): get Sanguis Draxonis, Radix Codonopsis, Radix Angelicae Pubescentis, Rhizoma Chuanxiong, Folium Mori, Semen Cucumidis sativi, Caulis Sargentodoxae and Radix Glycyrrhizae, pulverize after cleaning, drying, add the water soaking 1 hour of coarse powder total amount 8 times amount, then decoct 2 times, each 2 hours, filter, merging filtrate, filtrate is at 50 DEG C, vacuum is survey the clear paste that relative density is 1.10 under vacuum-concentrcted to 60 DEG C condition under the condition of 0.05MPa, cooling, slowly adds ethanol while stirring to alcohol content for reaching 60%, and 4 DEG C leave standstill 24 hours, filter, obtain filtrate A and filtering residue;
(3): the filtering residue obtained in (2) slowly being added while stirring its weight 4 times amount volume fraction is the ethanol of 60%, 4 DEG C leave standstill 3 hours, filter, obtain liquor B and filtering residue; Filtering residue uses the washing with alcohol 3 times of 60% again, collects and merges cleaning mixture;
(4): merge described filtrate A, liquor B and cleaning mixture, survey the thick paste that relative density is 1.10, drying under reduced pressure under mixing final vacuum is evaporated to 60 DEG C of conditions, pulverize, cross 100 mesh sieves, mix with described Ultra-fine Powder of Mulberry Leaves, to obtain final product.
embodiment 2:
Raw material is taken: Radix Cirsii Japonici 30 parts, Sanguis Draxonis 30 parts, Radix Codonopsis 28 parts, Radix Angelicae Pubescentis 20 parts, Rhizoma Chuanxiong 28 parts, 20 parts, Folium Mori, Semen Cucumidis sativi 18 parts, Caulis Sargentodoxae 20 parts and 20 parts, Radix Glycyrrhizae by following parts by weight.
Preparation method:
(1): get Radix Cirsii Japonici, wash away impurity, 50 DEG C of hot air dryings 5 hours, controlling moisture is 8%, pulverizes, and crosses 60 mesh sieves, obtains coarse powder; Coarse powder is sucked air-stream type ultrafine pulverizer and carry out micronizing, pulverize pressure 0.5MPa, charging rate is 30mg/s, carries out micronizing respectively after drying, crosses 800 mesh sieves, obtains Ultra-fine Powder of Mulberry Leaves, for subsequent use;
(2): get Sanguis Draxonis, Radix Codonopsis, Radix Angelicae Pubescentis, Rhizoma Chuanxiong, Folium Mori, Semen Cucumidis sativi, Caulis Sargentodoxae and Radix Glycyrrhizae, clean, crushed after being dried, add the water soaking 0.5 hour of coarse powder total amount 13 times amount, then decoct 3 times, each 1 hour, filter, merging filtrate, filtrate is at 65 DEG C, vacuum is survey the clear paste that relative density is 1.20 under vacuum-concentrcted to 60 DEG C condition under the condition of 0.08MPa, cooling, slowly adds ethanol while stirring to alcohol content for reaching 60%, and 4 DEG C leave standstill 12 hours, filter, obtain filtrate A and filtering residue;
(3): the filtering residue obtained in (2) slowly being added while stirring its weight 6 times amount volume fraction is the ethanol of 40%, 4 DEG C leave standstill 5 hours, filter, obtain liquor B and filtering residue; Filtering residue uses the washing with alcohol 2 times of 60% again, collects and merges cleaning mixture;
(4): merge described filtrate A, liquor B and cleaning mixture, survey the thick paste that relative density is 1.20, drying under reduced pressure under mixing final vacuum is evaporated to 60 DEG C of conditions, pulverize, cross 200 mesh sieves, mix with described Ultra-fine Powder of Mulberry Leaves, to obtain final product.
embodiment 3:
Raw material is taken: Radix Cirsii Japonici 28 parts, Sanguis Draxonis 28 parts, Radix Codonopsis 20 parts, Radix Angelicae Pubescentis 15 parts, Rhizoma Chuanxiong 16 parts, 18 parts, Folium Mori, Semen Cucumidis sativi 14 parts, Caulis Sargentodoxae 15 parts and 15 parts, Radix Glycyrrhizae by following parts by weight.
Preparation method:
(1): get Radix Cirsii Japonici, wash away impurity, 50 DEG C of hot air dryings 5 hours, controlling moisture is 5%, pulverizes, and crosses 50 mesh sieves, obtains coarse powder; Coarse powder is sucked air-stream type ultrafine pulverizer and carry out micronizing, pulverize pressure 0.5MPa, charging rate is 30mg/s, carries out micronizing respectively after drying, crosses 800 mesh sieves, obtains Ultra-fine Powder of Mulberry Leaves, for subsequent use;
(2): get Sanguis Draxonis, Radix Codonopsis, Radix Angelicae Pubescentis, Rhizoma Chuanxiong, Folium Mori, Semen Cucumidis sativi, Caulis Sargentodoxae and Radix Glycyrrhizae, clean, crushed after being dried, add the water soaking 0.5 hour of coarse powder total amount 10 times amount, then decoct 2 times, each 2 hours, filter, merging filtrate, filtrate is at 60 DEG C, vacuum is survey the clear paste that relative density is 1.20 under vacuum-concentrcted to 60 DEG C condition under the condition of 0.06MPa, cooling, slowly adds ethanol while stirring to alcohol content for reaching 50%, and 4 DEG C leave standstill 24 hours, filter, obtain filtrate A and filtering residue;
(3): the filtering residue obtained in (2) slowly being added while stirring its weight 5 times amount volume fraction is the ethanol of 50%, 4 DEG C leave standstill 4 hours, filter, obtain liquor B and filtering residue; Filtering residue uses the washing with alcohol 3 times of 50% again, collects and merges cleaning mixture;
(4): merge described filtrate A, liquor B and cleaning mixture, survey the thick paste that relative density is 1.20, drying under reduced pressure under mixing final vacuum is evaporated to 60 DEG C of conditions, pulverize, cross 200 mesh sieves, mix with described Ultra-fine Powder of Mulberry Leaves, to obtain final product.
The pharmaceutical composition of embodiment of the present invention 1-3 can be prepared as tablet, and concrete technology is as follows:
Take the pharmaceutical composition obtained in embodiment, add adjuvant mixing, described adjuvant comprises: the gelatin solution of starch, lactose, 5-20%, dried starch and distilled water, lubricant is added after combination drying, described lubricant is micropowder silica gel, tabletting, coating, obtains the tablet of embodiment of the present invention 1-3 pharmaceutical composition.
pharmaceutical composition pharmacodynamic study of the present invention
test example 1pharmaceutical composition of the present invention is on the impact of White Rabbit fracture model bone density
1, test material
(1) experimental animal: White Rabbit, male and female half and half, 1.5-2.5kg, are provided by Zhongshan University center; Get White Rabbit 50, be divided into 5 groups at random, often organize 10, be respectively model group (equal-volume normal saline), Radix Lamiophlomidis Rotatae group (1.0g/kg ﹒ d), pharmaceutical composition A of the present invention, B and C group;
(2) instrument: Hitachi 7020 automatic clinical chemistry analyzer, Japanese Hitachi company; Absorptiometry (Piximusbonedensito-meter, LUNAR company of the U.S.)
(3) trial drug: pharmaceutical composition A group of the present invention is pharmaceutical composition (0.81g/kg ﹒ d) prepared by embodiment 3; Pharmaceutical composition B group is pharmaceutical composition (0.81g/kg ﹒ d) prepared by embodiment 1; Pharmaceutical composition C group is pharmaceutical composition (0.81g/kg ﹒ d) prepared by embodiment 2; Radix Lamiophlomidis Rotatae capsule, Gansu Duyiwei Biological Pharmaceutical Co., Ltd, 0.3g*50 grain/bottle;
2, test method:
After White Rabbit adaptability raises one week, with 3% Nembutal sodium solution according to after the anesthesia of 1ml/kg dose intravenous, both sides forelimb cropping, 75% alcohol disinfecting, is aseptically widely about 3mm with horizontal being drilled to of medical operation dental burr epimere 1/3 intersection in the radius of both sides, go deep into medullary cavity and form bone injury, skin suture, Post operation starts gastric infusion, successive administration next day, within after administration one week, to get 7 in each group of rabbit to surrounding, measure indices; And intercepting both sides radius respectively at second week after administration, 4th week, its length comprises damage and each normal reach sclerotin up and down, measures bone density, observe union of fracture situation with U.S. LUNAR company Piximusbonedensito-meter analyzer.
3, result of the test
Table 1 pharmaceutical composition of the present invention is on the impact of White Rabbit fracture model bone density
▲compared with model group, p < 0.05;
▲ ▲compared with model group, p < 0.01.
4, conclusion
As shown in Table 1, successive administration is after two weeks, and the bone density of Radix Lamiophlomidis Rotatae group and pharmaceutical composition A of the present invention, B and C group increases all to some extent, and has significant difference (p < 0.05 or p < 0.01) compared with model group; After successive administration surrounding, Radix Lamiophlomidis Rotatae group and pharmaceutical composition A of the present invention, the amplitude that the bone density of B and C group increases are larger, much larger than the bone density after two weeks, and there is pole significant difference (p < 0.05 or p < 0.01) compared with model group; As can be seen here, pharmaceutical composition of the present invention has accelerates bone ore deposit sedimentation rate, improves bone density, promotes the function of fracture site healing.
test example 2pharmaceutical composition of the present invention is to the clinical observation on the therapeutic effect of fracture clinical volunteers patient
(1) diagnostic criteria
Determine that the diagnostic criteria of this test is as follows with reference to " new Chinese medicine guideline of clinical investigations " 2002 " guideline of clinical investigations of new Chinese medicine treatment traumatic fracture ":
1, Western medicine diagnose standard:
Traumatic fracture diagnostic criteria:
(1) trauma history of direct or indirect violence is had;
(2) General Symptoms: uncomplicated simple fracture, General Symptoms is not obvious or not serious; Shock can be there is or merge visceral organ injury in serious wound, combined injury; Open fracture can concurrent infection or and go crazy, blood vessel injury, there is corresponding General Symptoms;
(3) local symptom: pain pain and tenderness, swelling, dysfunction, deformity, abnormal movement, bony crepitus;
(4) x-ray inspection: the diagnosis that can clearly fracture, can confirm the localized variation such as classification of fracture, moving direction, fracture end form, and get rid of pathologisch Bruch.
2, tcm diagnosis standard:
(1) syndrome of qi stagnation and blood stasis: primary symptom: fracture, pain, swelling, ecchymosis; Secondary disease: thirsty, dark coloured urine, constipation, red tongue or have ecchymosis, yellow fur, floating and rapid pulse or stringy and tense pulse;
(2) the sluggish card of congestion: primary symptom: fracture does not connect or bone connects hard, and alleviation of pain, swells and disappear to the greatest extent; Secondary disease: dimly red tongue, yellow and thin fur, stringy pulse.
(3) deficiency of qi and blood card: primary symptom: bone connects not hard, dizziness and blurred vision, pale white complexion; Secondary disease: deficiency of QI with disinclination to talk, spiritlessness and weakness, light red tongue, thready pulse;
(4) caused by liver and kidney deficiency card: primary symptom: bone connects not hard, soreness of waist and knee joint, and limbs wither soft; Secondary disease: spiritlessness and weakness, light red tongue, thin fur, thready pulse.
(2) exclusion standard:
(1) pathologisch Bruch caused by osteopathia; (2) open fracture has soft tissue defects or the infected; (3) suckling gestation or preparing gestation women; (4) allergic constitution or to multi-medicament allergy sufferers; (5) severe primary disease and the psychotics such as the heart, brain, liver, kidney, hemopoietic system, hormonal system is merged; (6) state of an illness is critical, is difficult to make definite estimator to the effectiveness of new drug and safety.
(3) clinical trial
1, physical data: all selected fracture clinical volunteers patients are divided into two groups at random, treatment group 100 example, wherein male patient 56 example, female patient 44 example; Matched group 100 example, wherein male patient 55 example, female patient 45 example.Age is 20-80 year, 50.5 years old mean age.Two groups of influence factors such as age, symptom, through statistical procedures, there was no significant difference, meets a point set condition.
2, test method
Treatment group: take tablet (0.3g*100 sheet/bottle) prepared by the embodiment of the present invention 3, every day 3 times, each 3, serve on 3 months;
Matched group: take bone setting tablet (Pan Shoude, accurate word Z21021461, the 0.33g*36 sheet/box of traditional Chinese medicines), every day 3 times, each 4, serve on 3 months.
3, curative effect determinate standard
Effective: pain is eased substantially, fracture site is red, swollen, heat all obviously alleviates,
Effective: pain obtains larger alleviation, and fracture site is red, swollen, heat all alleviates;
Invalid: pain does not have alleviation, fracture site is red, swollen, heat does not all obtain and obviously alleviates.
4, therapeutic outcome, as shown in table 2.
Table 2 therapeutic effect
5, conclusion
This test adopts bone setting tablet as a control group, bone setting tablet has blood circulation promoting and blood stasis dispelling, reducing swelling and alleviating pain, effect of relaxing muscles and tendons bone strengthening, for traumatic injury, lumbar sprain and QI divergeny, injured in the sinews or bones, swelling and pain due to blood stasis, damage is red and swollen waits disease, by with the comparing of medicine composite for curing effect of the present invention, highlight the effect of pharmaceutical composition of the present invention in treatment fracture.Unexpectedly, pharmaceutical composition of the present invention reaches more than 80% for the obvious effective rate for the treatment of fracture, total effective rate is up to 95%, far above obvious effective rate and the total effective rate of matched group, visible, pharmaceutical composition of the present invention particularly the embodiment of the present invention 3 prepare tablet evident in efficacy, total effective rate is high, can be used as treatment fracture drug use.
Claims (6)
1. treat the pharmaceutical composition of fracture for one kind, it is characterized in that, described pharmaceutical composition is prepared from by the raw material of following parts by weight: Radix Cirsii Japonici 15-30 part, Sanguis Draxonis 15-30 part, Radix Codonopsis 14-28 part, Radix Angelicae Pubescentis 10-20 part, Rhizoma Chuanxiong 12-28 part, Folium Mori 15-20 part, Semen Cucumidis sativi 10-18 part, Caulis Sargentodoxae 10-20 part and Radix Glycyrrhizae 10-20 part.
2. the pharmaceutical composition for the treatment of fracture as claimed in claim 1, it is characterized in that, described pharmaceutical composition is prepared from by the raw material of following parts by weight: Radix Cirsii Japonici 15 parts, Sanguis Draxonis 15 parts, Radix Codonopsis 14 parts, Radix Angelicae Pubescentis 10 parts, Rhizoma Chuanxiong 12 parts, 15 parts, Folium Mori, Semen Cucumidis sativi 10 parts, Caulis Sargentodoxae 10 parts and 10 parts, Radix Glycyrrhizae.
3. the pharmaceutical composition for the treatment of fracture as claimed in claim 1, it is characterized in that, described pharmaceutical composition is prepared from by the raw material of following parts by weight: Radix Cirsii Japonici 30 parts, Sanguis Draxonis 30 parts, Radix Codonopsis 28 parts, Radix Angelicae Pubescentis 20 parts, Rhizoma Chuanxiong 28 parts, 20 parts, Folium Mori, Semen Cucumidis sativi 18 parts, Caulis Sargentodoxae 20 parts and 20 parts, Radix Glycyrrhizae.
4. the pharmaceutical composition for the treatment of fracture according to claim 1, it is characterized in that, described pharmaceutical composition is prepared from by the raw material of following parts by weight: Radix Cirsii Japonici 28 parts, Sanguis Draxonis 28 parts, Radix Codonopsis 20 parts, Radix Angelicae Pubescentis 15 parts, Rhizoma Chuanxiong 16 parts, 18 parts, Folium Mori, Semen Cucumidis sativi 14 parts, Caulis Sargentodoxae 15 parts and 15 parts, Radix Glycyrrhizae.
5. the pharmaceutical composition of the treatment fracture as described in any one of claim 1-4, is characterized in that: described pharmaceutical composition is made into Chinese medicine decoction, granule, powder, capsule, watered pill or tablet.
6. a preparation method for the pharmaceutical composition of the treatment fracture as described in any one of claim 1-4, is characterized in that, comprise the steps:
(1): get Folium Mori, wash away impurity, 50 DEG C of hot air dryings 5 hours, control moisture is 3-8%, pulverizes, and crosses 40-60 mesh sieve, obtains coarse powder; Coarse powder is sucked air-stream type ultrafine pulverizer and carry out micronizing, pulverize pressure 0.5MPa, charging rate is 30mg/s, carries out micronizing respectively after drying, crosses 800 mesh sieves, obtains Ultra-fine Powder of Mulberry Leaves, for subsequent use;
(2): get Sanguis Draxonis, Radix Codonopsis, Radix Angelicae Pubescentis, Rhizoma Chuanxiong, Folium Mori, Semen Cucumidis sativi, Caulis Sargentodoxae and Radix Glycyrrhizae, clean, crushed after being dried, add the water soaking 0.5-1 hour of coarse powder total amount 8-13 times amount, then decoct 2-3 time, each 1-2 hour, filter, merging filtrate, filtrate is at 50-65 DEG C, vacuum is survey the clear paste that relative density is 1.10-1.20 under vacuum-concentrcted to 60 DEG C condition under the condition of 0.05-0.08MPa, cooling, slowly adds ethanol while stirring to alcohol content for reaching 40-60%, 4 DEG C of standing 12-24 hour, filter, obtain filtrate A and filtering residue;
(3): the filtering residue obtained in (2) slowly being added while stirring its weight 4-6 times amount volume fraction is the ethanol of 40-60%, 4 DEG C of standing 3-5 hour, filter, obtain liquor B and filtering residue; Filtering residue uses the washing with alcohol 2-3 time of 40-60% again, collects and merges cleaning mixture;
(4): merge described filtrate A, liquor B and cleaning mixture, survey the thick paste that relative density is 1.10-1.20, drying under reduced pressure under mixing final vacuum is evaporated to 60 DEG C of conditions, pulverize, cross 100-200 mesh sieve, mix with described Ultra-fine Powder of Mulberry Leaves, to obtain final product.
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510651443.1A CN105125799A (en) | 2015-10-10 | 2015-10-10 | Medicine composition for treating bone fractures and preparing method of medicine composition |
CN201610306340.6A CN105943791A (en) | 2015-10-10 | 2015-10-10 | Method for preparing pharmaceutical composition for treating fractures |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510651443.1A CN105125799A (en) | 2015-10-10 | 2015-10-10 | Medicine composition for treating bone fractures and preparing method of medicine composition |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201610306340.6A Division CN105943791A (en) | 2015-10-10 | 2015-10-10 | Method for preparing pharmaceutical composition for treating fractures |
Publications (1)
Publication Number | Publication Date |
---|---|
CN105125799A true CN105125799A (en) | 2015-12-09 |
Family
ID=54711612
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201510651443.1A Withdrawn CN105125799A (en) | 2015-10-10 | 2015-10-10 | Medicine composition for treating bone fractures and preparing method of medicine composition |
CN201610306340.6A Withdrawn CN105943791A (en) | 2015-10-10 | 2015-10-10 | Method for preparing pharmaceutical composition for treating fractures |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201610306340.6A Withdrawn CN105943791A (en) | 2015-10-10 | 2015-10-10 | Method for preparing pharmaceutical composition for treating fractures |
Country Status (1)
Country | Link |
---|---|
CN (2) | CN105125799A (en) |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103055197A (en) * | 2012-12-26 | 2013-04-24 | 柳州市中医院 | Traditional Chinese medicine for treating lumbar compression fracture and preparation method thereof |
CN104547489A (en) * | 2014-12-31 | 2015-04-29 | 曾子维 | Use of traditional Chinese medicine composition in preparation of medicine for treating comminuted fracture |
CN104958429A (en) * | 2015-08-04 | 2015-10-07 | 青岛蓝盛洋医药生物科技有限责任公司 | Traditional Chinese medicinal composition for treating geriatric fracture and preparation method thereof |
CN104958416A (en) * | 2015-07-28 | 2015-10-07 | 青岛蓝盛洋医药生物科技有限责任公司 | Chinese medicinal preparation for treating sciatica and preparation method thereof |
-
2015
- 2015-10-10 CN CN201510651443.1A patent/CN105125799A/en not_active Withdrawn
- 2015-10-10 CN CN201610306340.6A patent/CN105943791A/en not_active Withdrawn
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103055197A (en) * | 2012-12-26 | 2013-04-24 | 柳州市中医院 | Traditional Chinese medicine for treating lumbar compression fracture and preparation method thereof |
CN104547489A (en) * | 2014-12-31 | 2015-04-29 | 曾子维 | Use of traditional Chinese medicine composition in preparation of medicine for treating comminuted fracture |
CN104958416A (en) * | 2015-07-28 | 2015-10-07 | 青岛蓝盛洋医药生物科技有限责任公司 | Chinese medicinal preparation for treating sciatica and preparation method thereof |
CN104958429A (en) * | 2015-08-04 | 2015-10-07 | 青岛蓝盛洋医药生物科技有限责任公司 | Traditional Chinese medicinal composition for treating geriatric fracture and preparation method thereof |
Also Published As
Publication number | Publication date |
---|---|
CN105943791A (en) | 2016-09-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN108619478A (en) | A kind of Chinese medicine preparation for treating treating rheumatic ostealgia | |
CN104826036A (en) | Composite traditional Chinese medicine composition for treating hyperplasia of mammary glands and method for manufacturing composite traditional Chinese medicine composition | |
CN104288228A (en) | Traditional Chinese medicine composite for treating pain in neck, shoulders, waist and legs | |
CN103263601B (en) | Chinese herbal preparation for accelerating fracture post-operation healing and preparation method of Chinese herbal preparation | |
CN104815318A (en) | Traditional Chinese medicine preparation for treating gout | |
CN104971140A (en) | Medicine composition for treating bone fracture and preparation method thereof | |
CN106266046A (en) | A kind of Chinese medicine composition treating cold rheumatoid joint pain and preparation method | |
CN102743550B (en) | Medicine composition for accelerating healing after fracture surgery, preparation method and application | |
CN104524080A (en) | Traditional Chinese medicine preparation for treating injuries from falls, fractures, contusions and strains and preparation method | |
CN104398664A (en) | Zhuang pharmaceutical composition for treating anovulatory infertility | |
CN105125799A (en) | Medicine composition for treating bone fractures and preparing method of medicine composition | |
CN105250403A (en) | Medicine composition for treating bone fracture and preparation method thereof | |
CN110680849B (en) | Oral traditional Chinese medicine formula for treating fracture | |
CN105168537A (en) | Compound medicine for treating bone fracture and preparation method of compound medicine | |
CN105213481A (en) | A kind of pharmaceutical composition for the treatment of fracture and preparation method thereof | |
CN105267292A (en) | Pharmaceutical composition for treating bone fracture and preparation method of pharmaceutical composition for treating bone fracture | |
CN105311183A (en) | Pharmaceutical composition containing folium artemisiae argyi for treating fracture and preparation method of pharmaceutical composition | |
CN104771529A (en) | Drug for treating traumatic arthritis caused by deficiencies in liver and kidney and preparation method thereof | |
CN104873858A (en) | Traditional Chinese medicine composition for treating functional dysmenorrheal | |
CN105327299A (en) | Medicine for treating idiopathic thrombocytopenic purpura | |
CN104547862A (en) | Use of traditional Chinese medicine preparation in preparation of medicine for treating bone fracture | |
CN104740396A (en) | Traditional Chinese medicine for treating kidney stones and preparation method of traditional Chinese medicine | |
CN104623553A (en) | Traditional Chinese medicine composition for treating annexitis | |
CN103690816A (en) | Traditional Chinese medicinal composition for eliminating spleen insufficiency, phlegm dampness and breast cystic hyperplasia and preparation method thereof | |
CN103330896A (en) | Preparation method of powder for treating postpartum nonspecific vaginitis |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
WW01 | Invention patent application withdrawn after publication |
Application publication date: 20151209 |
|
WW01 | Invention patent application withdrawn after publication |